Want tender expert help? See our tender preparation service
Tenders

UHB-SWBH Exa-cel subcontract 25/26

Closed
Deadline
Deadline not specified
Contract Details
Category
Negotiated Procedure
Reference
013225-2026
Value
£54,000
Location
West Midlands, United Kingdom
Published
September 25, 2026
CPV Code
Project Timeline

Tender Published

February 13, 2026

Contract Start Date

February 09, 2026

Buyer IntelligencePRO
🔒
Unlock Buyer Intelligence
See spending patterns, preferred procedures, and more.
Upgrade to Professional →
View Original
Budget
£54,000
Duration
13 months
Location
West Midlands
Type
Negotiated Procedure

Original Tender Description

Subcontract for the provision of care of patients being treated with Exagamglogene autotemcel (Exa-cel/Casgevy) for transfusion dependent β-thalassaemia or severe sickle cell disease UHB-SWBH Exa-cel subcontract 25/26

Risk Analysis

Risk analysis is not yet available for this country's tenders. Currently supported: Estonia, Latvia, Lithuania, Poland, France, UK, Denmark, Netherlands, Norway, and Finland.

Win Strategy

Get an AI-powered winning strategy tailored to this tender. Includes win probability score, key opportunities and challenges, recommended bid focus areas, competitive positioning insights, and actionable recommendations to maximize your chances.

Login

Competitors

Upgrade to see which companies are likely to bid on this tender, based on historical procurement data.

Login

Requirements & Qualifications

AI extracts and organizes all requirements from tender documents — mandatory qualifications, technical specifications, financial conditions, and submission rules — clearly categorized so you know exactly what's needed to bid.

Login

Basic Requirements

  • Company registration in EU required
  • Proven track record in similar projects
  • Financial stability documentation

Documents

3 documents available with AI summaries

OCDS RecordDOC
013225-2026_ocds_record.json

This OCDS record provides structured data detailing an awarded subcontract by University Hospitals Birmingham NHS Foundation Trust for patient care involving Exagamglogene autotemcel (Exa-cel/Casgevy) for specific blood disorders.

OCDS Release PackageDOC
013225-2026_ocds_release.json

This OCDS Release Package provides structured data detailing the tender process and contract award for a subcontract to provide care for patients receiving Exagamglogene autotemcel treatment for transfusion-dependent β-thalassaemia or severe sickle cell disease, involving University Hospitals Birmingham NHS Foundation Trust and Sandwell & West Birmingham Hospitals NHS Trust.

Official PDF VersionPDF
013225-2026_official.pdf

This document is a notice of a subcontract awarded to Sandwell & West Birmingham Hospitals NHS Trust for the provision of care to patients treated with Exa-cel for specific blood disorders, valued at £45,000 and running from February 2026 to March 2027.

Documents Preview

Sign up to view document summaries and analysis

Quality Score

Comprehensive quality analysis of this tender scoring legal compliance, clarity, completeness, fairness, practicality, data consistency, and sustainability on a 0-100 scale with detailed breakdown and recommendations.

Login
✨Want us to handle this tender?Let's Win This Tender